Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Rheumatoid Arthritis Clinical Trial

— CREDO 1  

Official title:

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02760368
• Other study ID #: CL04041022
• Secondary ID: 2014-004719-36
• Status: Completed
• Phase: Phase 3
• Start date: May 19, 2016
• Est. completion date: October 2018

Study information

• Verified date: September 2023
• Source: R-Pharm
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate (MTX). The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA) inadequately controlled by methotrexate (MTX) therapy.

Description:

The goal of this Phase III study was to assess the efficacy, tolerability, and safety of OKZ in subjects with moderately to severely active RA who had responded inadequately to MTX. The primary endpoint of the trial was at Week 12. Olokizumab was expected to reduce the disease activity and improve physical function. The study was expected to provide safety information in a large group of subjects over at least a 24 week period. The CREDO 1 study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to Week 24, and a Safety Follow-Up Period from Week 24 to Week 44. At randomization, a total of 428 eligible subjects were randomly assigned to 1 of 3 treatment groups in a 1:1:1 ratio: 1. OKZ 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of placebo OKZ q4w to maintain blinding) + MTX. 2. OKZ 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX. 3. Placebo: SC injection of placebo q2w + MTX Throughout the double-blind Treatment Period, all subjects were required to remain on a stable dose of background MTX at 15 to 25 mg/week (or ≥ 10 mg/week if there was documented intolerance to higher doses) with a stable route of administration, and concomitant treatment with folic acid ≥5 mg per week or equivalent is required for all subjects. The last dose of study treatment (OKZ or placebo) was at Week 22 in all groups. Following Visit 2 (randomization), subjects returned to the study site at least every other week through Week 24 for response and safety assessments as per the study Schedule of Events. Subjects were classified in terms of their response to study treatment at Week 14, with non-responders defined as subjects in any treatment group who had not improved by at least 20% in both swollen and tender joint counts (66-68 joint assessment). Starting at or as close as possible to Week 14, non-responders were administered sulfasalazine and/or hydroxychloroquine as rescue medication in addition to the assigned treatment. After completion of the 24-week double-blind Treatment Period, subjects either rolled over into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period. During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after the last dose of study treatment. Subjects who discontinued the randomized treatment prematurely were required to come for the End of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then continued with the scheduled study visits as per the Schedule of Events. The study was conducted at approximately 50 sites across 4 countries globally, which included Russia, Belarus, Turkey, and Bulgaria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 428
• Est. completion date: October 2018
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects may be enrolled in the study only if they meet all of the following criteria:

• Subjects willing and able to sign informed consent
• Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised classification criteria for RA for at least 12 weeks prior to Screening.
• Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at a dose of 15 to 25 mg/week (or =10 mg/week if intolerant to higher doses).
• The dose and means of administering MTX must have been stable for at least 6 weeks prior to Screening.
• Subjects must be willing to take folic acid or equivalent throughout the study
• Subjects must have moderately to severely active RA disease as defined by all of the

following:

• =6 tender joints (68 joint count) at Screening and baseline; and
• =6 swollen joints (66 joint count) at Screening and baseline; and
• CRP above ULN at Screening based on the central laboratory results.

Exclusion Criteria:

• Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus). However, subjects could have secondary Sjogren's syndrome or hypothyroidism
• Subjects who were Steinbrocker class IV functional capacity (incapacitated, largely or wholly bed-ridden or confined to a wheelchair, with little or no self-care)
• Prior exposure to any licensed or investigational compound directly or indirectly targeting IL-6 or IL-6R (including tofacitinib or other Janus kinases and spleen tyrosine kinase [SYK] inhibitors)
• Prior treatment with cell-depleting therapies, including anti-CD20 or investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, and anti-CD19)
• Prior use of bDMARDs, with the following exception:
• Subjects who discontinued TNFi therapy due to a reason other than lack of efficacy were allowed to enter the study (TNFi therapy was not to be discontinued to facilitate a subject's participation in the study but should instead have been previously discontinued as part of a subject's medical management of RA). The use of TNFi therapy

within the following windows prior to baseline was exclusionary:

1. 4 weeks for etanercept

2. 8 weeks for infliximab

3. 10 weeks for adalimumab, certolizumab, and golimumab

• Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to baseline
• Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent), or change in dosage within 2 weeks prior to baseline
• Prior documented history of no response to hydroxychloroquine and sulfasalazine
• Prior use of cDMARDs (other than MTX) within the following windows prior to baseline (cDMARDs were not to be discontinued to facilitate a subject's participation in the study, but should instead have been previously discontinued as part of a subject's

medical management of RA):

1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine, chloroquine, gold, penicillamine, minocycline, or doxycycline

2. 12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a dosage of 50 grams 4 times daily for at least 24 hours

3. 24 weeks for cyclophosphamide

• Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination with live vaccines during the study
• Participation in any other investigational drug study within 30 days or 5 times the terminal half-life of the investigational drug, whichever is longer, prior to baseline
• Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to baseline
• Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline
• Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of NSAIDs within 2 weeks prior to baseline
• Previous participation in this study (randomized) or another study of OKZ
• Subjects with acute or chronic viral hepatitis B or C infection as detected by blood tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg], total hepatitis B core antibody [anti-HBc], or hepatitis C virus antibody [HCV Ab]) a. Subjects who were positive for hepatitis B surface antibody (anti-HBs), but negative for HBsAg and anti-HBc, were eligible
• Subjects with HIV infection
• Subjects with:

1. Suspected or confirmed current active TB disease or a history of active TB disease

2. Close contact (i.e., sharing the same household or other enclosed environment, such as a social gathering place, workplace, or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening.

• Concurrent malignancy or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma in situ of the cervix and successfully treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to Screening [and no more than 3 excised skin cancers within the last 5 years prior to Screening])
• Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2 weeks prior to Screening or at baseline, injectable anti-infective therapy in the last 4 weeks prior to baseline, or serious or recurrent infection with a history of hospitalization in the 6 months prior to baseline
• Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other non-self-limited herpes zoster infections in the 6 months prior to baseline
• Subjects with planned surgery during the study or surgery =4 weeks prior to Screening and from which the subject had not fully recovered, as judged by the Investigator
• Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with a history of such predisposing conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)
• Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis and optic neuritis)
• History of chronic alcohol or drug abuse as judged by the Investigator
• Female subjects who are pregnant, currently lactating, have lactated within the last 12 weeks, or who were planning to become pregnant during the study or within 6 months of last dose of study treatment
• Female subjects of childbearing potential (unless permanent cessation of menstrual periods, determined retrospectively after a woman had experienced 12 months of natural amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age] or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone levels >40 mIU/mL and estradiol <20 pg/mL) who were not willing to use a highly effective method of contraception during the study and for at least 6 months after the last administration of study treatment OR Male subjects with partners of childbearing potential not willing to use a highly effective method of contraception during the study and for at least 3 months after the last administration of study treatment;
• Subjects with a known hypersensitivity to any component of the OKZ drug product, or placebo
• Subjects with a known hypersensitivity or contraindication to any component of the rescue medication
• History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Drug:
• Olokizumab
160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial
• Placebo
sodium chloride 0.9% solution supplied in polypropylene plastic ampoules of 10 mL cartons to contain 10 ampoules

Locations

Country	Name	City	State
Belarus	City Clinical Hospital #1	Minsk
Belarus	Vitebsk Regional Clinical Hospital	Vitebsk
Bulgaria	DCC 'Sv. Pantaleymon' OOD	Pleven
Bulgaria	UMHAT "Kaspela", EOOD	Plovdiv
Bulgaria	MC "Synexus - Sofia", EOOD	Sofia
Bulgaria	UMHAT "Sv. Ivan Rilski", EAD	Sofia
Russian Federation	Regional State Budgetary Healthcare Institution "Barnaul City Hospital #4"	Barnaul	Altai Region
Russian Federation	SBEI HPE "Ural State Medical University" of MoH of RF based MBI "Central City Clinical Hospital #6"	Ekaterinburg	Sverdlovskaya Oblast
Russian Federation	State Budgetary Healthcare Institution of Sverdlovsk Region "Sverdlovsk Regional Clinical Hospital #1"	Ekaterinburg	Sverdlovskaya Oblast
Russian Federation	State Autonomous Healthcare Institution "Republican Clinical Hospital of Ministry of Health of Tatarstan Republic	Kazan'	The Republic Of Tatarstan
Russian Federation	Medical Center LLC "Maksimum Zdoroviya"	Kemerovo	Kemerovo Oblast
Russian Federation	SAHI of Kemerovo region "Regional Clinical Hospital for War Veterans"	Kemerovo	Kemerovskaya Oblast
Russian Federation	Budgetary Healthcare Institution "Kursk Regional Clinical Hospital" of Healthcare Committee of Kursk region	Kursk	Kurskaya Oblast
Russian Federation	FSBEI HE "First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation", UCH #1	Moscow	Moscovskaya Oblast
Russian Federation	FSBEI HE "FMSMU n.a. I.M. Sechenov of MoH of RF", University Hospital #2, Departament of New Drugs Introduction	Moscow	Moscovskaya Oblast
Russian Federation	FSBSI "Scientific Research Institute of Rheumatology n.a. V.A. Nasonova"	Moscow
Russian Federation	SBEI HPE "First Moscow State Medical University n.a. I.M. Sechenov of MoH of Russian Federation" UCH #3	Moscow	Moscovskaya Oblast
Russian Federation	SBHI of Moscow "City Clinical Hospital #4 of Moscow Healthcare Departament"	Moscow	Moskovskaya Oblast
Russian Federation	State Budgetary Healthcare Institution "City Clinical Hospital # 15 n.a O.M. Filatov" of Moscow Healtheare Department	Moscow	Moscow Region
Russian Federation	State Budgetary Healthcare Institution of Moscow "City Clinical Hospital #1 n.a. Pirogov" Healthcare Departament of Moscow	Moscow	Moscovskaya Oblast
Russian Federation	SBHI of Nizhny Novgorod Region "Nizhny Novgorod Regional Clinical Hospital n.a.Semashko"	Nizhniy Novgorod	Nizhegorodskaya Oblast
Russian Federation	City Clinical Hospital ?5 of Nizhny Novgorod	Nizhny Novgorod
Russian Federation	State Autonomous Healthcare Institution of Novosibirsk region "City Polyclinic #1"	Novosibirsk	Novosibirsk Oblast
Russian Federation	Budgetary Healthcare Institution of Omsk Region "Regional Clinical Hospital"	Omsk	Omskaya Oblast
Russian Federation	LLC "Clinical Diagnostic Center "Ultramed"	Omsk	Omskaya Oblast
Russian Federation	SBHI of the Republic of Karelia "Republican Hospital named after V.A. Baranov"	Petrozavodsk	Republic Of Karelia
Russian Federation	SBEI HPE "Rostov State Medical University" of Ministry of Health of the Russian Federation	Rostov	Rostovskaya Oblast
Russian Federation	Ryazan State Medical University n.a. I.P. Pavlov based on Regional Clinical Cardiology Dispensary	Ryazan
Russian Federation	SBHI "North-West Federat Medical Research Center n.a. V.A.Almazov" of the Ministry of Healthcare of the Russian Federation	Saint Petersburg
Russian Federation	SPb SBHI "Clinical Rheumatological Hospital #25", Fourth Rheumatology Unit	Saint Petersburg	Leningradskaya Oblast
Russian Federation	SBEI HPE "SSMU n.a. V.I. Razumovsky of MoH of RF", Clinical Hospital n.a. S.R. Mirotvorcev, Therapeutic Departament	Saratov	Saratovskaya Oblast
Russian Federation	State Healthcare Institution "Regional Clinical Hospital"	Saratov	Saratovskaya Oblast
Russian Federation	Non-governmental Healtheare Institution "Regional Clinical Hospital at Smolensk station of OJSC "Russian Railways"	Smolensk	Smolenskaya Oblast
Russian Federation	SBHI of Stavropol Region "Stavropol Regional Clinical Hospital"	Stavropol'	Stavropol Region
Russian Federation	State Healthcare Institution of Tula region "Tula Regional Clinical Hospital"	Tula	Tulskaya Oblast
Russian Federation	State Budgetary Healthcare Institution "Republican Clinical Hospital n.a. G.G. Kuvatov"	Ufa	Respublic Of Bashkortostan
Russian Federation	State Healthcare Institution "Ulyanovsk Regional Clinical Hospital"	Ulyanovsk	Ulyanovskaya Oblast
Russian Federation	SBHI of Vladimir Region "Regional Clinical Hospital", Rheumatology Departament	Vladimir	Vladimirskaya Oblast
Russian Federation	SBHI "Yaroslavl Regional Clinical Hospital", Rheumatology department	Yaroslavl'	Yaroslavskaya Oblast
Russian Federation	State Autonomous Helthcare Institution of Yaroslavl region "Clinical Hospital of Emergency Care n.a. Solovyev"	Yaroslavl'	Yaroslavsakaya Oblast

Sponsors (4)

Lead Sponsor	Collaborator
R-Pharm International, LLC	Mene Research, OCT Clinical Trials, Quintiles, Inc.

Countries where clinical trial is conducted

Belarus,  Bulgaria,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response	A responder was defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.; The calculations were based on a = 20% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a = 20% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).	at Week 12
Secondary	Percentage of Subjects Achieving Low Disease Activity	Defined as Disease Activity Score 28 (DAS28) (CRP) < 3.2, and remaining on randomized treatment and in the study at Week 12.	at Week 12
Secondary	Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI)	Change of physical ability from baseline (the last available assessment prior to the first dose of the study treatment) to week 12, as measured by HAQ-DI. The HAQ-DI total score ranges from 0 (the best outcome) to 3 (the worst outcome).The HAQ-DI assesses the degree of difficulty experienced in 8 domains (dressing and grooming, arising, eating, walking, hygiene, reach, grip, common daily activities) of daily living activities using 20 questions. Each domain consists of 2 or 3 items. For each question the level of difficulty is scored from 0 (without any difficulty, the best outcome) to 3 (unable to do, the worst outcome). Each category is given a score by taking the maximum score of each question. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. If fewer than 6 categories had responses, no disability score was calculated.	Baseline to Week 12
Secondary	Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response	A responder was defined as any subject satisfying ACR50 criteria and remaining on randomized treatment and in the study at Week 24.; The calculations were based on a = 50% improvement from baseline in the swollen joint count (SJC) assessed in 66 joints and in the tender joint count (TJC) assessed in 68 joints; and a = 50% improvement from baseline in at least 3 of the 5 remaining core set measures: Patient Global Assessment of Disease Activity (Visual Analog Scale (VAS) assessment), Patient Assessment of Pain (VAS assessment), Health Assessment Questionnaire-Disability Index (HAQ-DI), Physician Global Assessment (VAS assessment), Level of acute phase reactant (CRP or ESR, using level of CRP in this study).	at Week 24
Secondary	Percentage of Subjects With Clinical Disease Activity Index (CDAI) = 2.8 (Remission)	Percentage of subjects with Clinical Disease Activity Index (CDAI) = 2.8 (remission) and remaining on randomized treatment and in the study at Week 24	at Week 24

External Links

•   E. Nasonov, M. Ivanova, M. Samsonov, T. Tyabut, M. C. Genovese; 2020 THU0176 Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results CREDO-1 study
•   E. Nasonov, R. Stoilov, T. Tyabut, M. C. Genovese. 2020 OP0021 Olokizumab, Monoclonal Antibody Against IL6, in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate:Results of Phase III CREDO-1 study
•   Nasonov E, Fatenejad S, Korneva E, Krechikova D. - Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate - CREDO1 Study [abstract].